FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987168596> ?p ?o ?g. }

• W1987168596 endingPage "15" @default.
• W1987168596 startingPage "15" @default.
• W1987168596 abstract "Clinical use of gadobutrol for contrast-enhanced magnetic resonance imaging of neurological diseases Kenneth T Cheng1, Hannah Y Cheng2, Kam Leung31Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA; 2Freelance Technical Writer, New Orleans, LA, USA; 3National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USAAbstract: Contrast-enhanced magnetic resonance imaging (CE-MRI) is an important clinical tool for diagnosing neurological diseases. The appropriate use of a suitable MRI contrast agent or contrast pharmaceutical is essential for CE-MRI to produce desirable diagnostic images. Currently, there are seven contrast agents (CAs) or pharmaceuticals approved for clinical imaging of the central nervous system (CNS) in the US, Europe, or Japan. All of the clinically approved CAs are water-soluble gadolinium-based contrast agents (GBCAs) which do not penetrate the CNS blood–brain barrier (BBB). These agents are used for imaging CNS areas without a BBB, or various pathologies, such as tumors and infection that break down the BBB and allow CAs to enter into the surrounding parenchyma. Clinically, GBCAs are most useful for detecting primary and secondary cerebral neoplastic lesions. Among these CNS GBCAs, gadobutrol (Gd-BT-DO3A, Gadovist™) is a neutral, nonionic, macrocyclic compound that showed promising results from clinical trials of CNS imaging. In comparison with other GBCAs, Gd-BT-DO3A has relatively high in vitro kinetic stability and r1 relaxivity. Gd-BT-DO3A has been recently approved by the US Food and Drug Administration (FDA) in 2011 for CNS imaging. A review of available literature shows that Gd-BT-DO3A exhibits similar safety and clinical efficacy profiles to other GBCAs. Gd-BT-DO3A has the distinguishing feature that it is the only clinical agent commercially available in a formulation of 1.0 M concentration with a relatively higher in vitro T1 shortening per unit volume than other clinical GBCAs which are only available in 0.5 M concentration. This double concentration of Gd-BT-DO3A may allow a relatively higher concentration of the agent to localize in the CNS and produce a better contrast enhancement at the same clinical dose as other GBCAs. Several recent published multicenter clinical trials appeared to support this potential advantage of Gd-BT-DO3A.Keywords: Gadovist, Gd-BT-DO3A, CE-MRI, CNS imaging, MRI contrast agent, gadolinium" @default.
• W1987168596 created "2016-06-24" @default.
• W1987168596 creator A5005382198 @default.
• W1987168596 date "2012-02-01" @default.
• W1987168596 modified "2023-09-24" @default.
• W1987168596 title "Clinical use of gadobutrol for contrast-enhanced magnetic resonance imaging of neurological diseases" @default.
• W1987168596 cites W111035113 @default.
• W1987168596 cites W1963655497 @default.
• W1987168596 cites W1966418790 @default.
• W1987168596 cites W1967287397 @default.
• W1987168596 cites W1975077872 @default.
• W1987168596 cites W1985305470 @default.
• W1987168596 cites W1986412998 @default.
• W1987168596 cites W1991456059 @default.
• W1987168596 cites W1992800232 @default.
• W1987168596 cites W1994334402 @default.
• W1987168596 cites W1995071576 @default.
• W1987168596 cites W1995257746 @default.
• W1987168596 cites W2001835802 @default.
• W1987168596 cites W2013470395 @default.
• W1987168596 cites W2018109914 @default.
• W1987168596 cites W2020092214 @default.
• W1987168596 cites W2022868149 @default.
• W1987168596 cites W2025344057 @default.
• W1987168596 cites W2037241290 @default.
• W1987168596 cites W2038087730 @default.
• W1987168596 cites W2039754233 @default.
• W1987168596 cites W2040490841 @default.
• W1987168596 cites W2043087048 @default.
• W1987168596 cites W2044957933 @default.
• W1987168596 cites W2058552326 @default.
• W1987168596 cites W2058710711 @default.
• W1987168596 cites W2061612871 @default.
• W1987168596 cites W2061928584 @default.
• W1987168596 cites W2061948232 @default.
• W1987168596 cites W2062908261 @default.
• W1987168596 cites W2070308380 @default.
• W1987168596 cites W2072052518 @default.
• W1987168596 cites W2077853709 @default.
• W1987168596 cites W2088837451 @default.
• W1987168596 cites W2089934112 @default.
• W1987168596 cites W2100095818 @default.
• W1987168596 cites W2111878477 @default.
• W1987168596 cites W2112942188 @default.
• W1987168596 cites W2121704606 @default.
• W1987168596 cites W2134831197 @default.
• W1987168596 cites W2136421454 @default.
• W1987168596 cites W2171633513 @default.
• W1987168596 cites W2318895935 @default.
• W1987168596 cites W2319260086 @default.
• W1987168596 cites W2320333585 @default.
• W1987168596 cites W2321151751 @default.
• W1987168596 cites W2322781671 @default.
• W1987168596 cites W2333106507 @default.
• W1987168596 cites W2411076863 @default.
• W1987168596 doi "https://doi.org/10.2147/rmi.s20665" @default.
• W1987168596 hasPublicationYear "2012" @default.
• W1987168596 type Work @default.
• W1987168596 sameAs 1987168596 @default.
• W1987168596 citedByCount "3" @default.
• W1987168596 countsByYear W19871685962019 @default.
• W1987168596 countsByYear W19871685962020 @default.
• W1987168596 countsByYear W19871685962021 @default.
• W1987168596 crossrefType "journal-article" @default.
• W1987168596 hasAuthorship W1987168596A5005382198 @default.
• W1987168596 hasBestOaLocation W19871685961 @default.
• W1987168596 hasConcept C118552586 @default.
• W1987168596 hasConcept C126322002 @default.
• W1987168596 hasConcept C126838900 @default.
• W1987168596 hasConcept C142724271 @default.
• W1987168596 hasConcept C143409427 @default.
• W1987168596 hasConcept C178790620 @default.
• W1987168596 hasConcept C185592680 @default.
• W1987168596 hasConcept C2776875665 @default.
• W1987168596 hasConcept C2989005 @default.
• W1987168596 hasConcept C529278444 @default.
• W1987168596 hasConcept C557651011 @default.
• W1987168596 hasConcept C58693492 @default.
• W1987168596 hasConcept C71924100 @default.
• W1987168596 hasConceptScore W1987168596C118552586 @default.
• W1987168596 hasConceptScore W1987168596C126322002 @default.
• W1987168596 hasConceptScore W1987168596C126838900 @default.
• W1987168596 hasConceptScore W1987168596C142724271 @default.
• W1987168596 hasConceptScore W1987168596C143409427 @default.
• W1987168596 hasConceptScore W1987168596C178790620 @default.
• W1987168596 hasConceptScore W1987168596C185592680 @default.
• W1987168596 hasConceptScore W1987168596C2776875665 @default.
• W1987168596 hasConceptScore W1987168596C2989005 @default.
• W1987168596 hasConceptScore W1987168596C529278444 @default.
• W1987168596 hasConceptScore W1987168596C557651011 @default.
• W1987168596 hasConceptScore W1987168596C58693492 @default.
• W1987168596 hasConceptScore W1987168596C71924100 @default.
• W1987168596 hasLocation W19871685961 @default.
• W1987168596 hasLocation W19871685962 @default.
• W1987168596 hasOpenAccess W1987168596 @default.
• W1987168596 hasPrimaryLocation W19871685961 @default.
• W1987168596 hasRelatedWork W1967287397 @default.
• W1987168596 hasRelatedWork W1989909269 @default.

• next